12 results
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
in Acute GVHD #Pathophys ... #Honc #GVHD #GraftVersusHostDisease ... #NEJM
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Adverse Events #Pathophys ... #Honc #ImmuneRelatedAdverseEvents ... Immunotherapy #NEJM
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Regulation by Heme #Pathophys ... #Honc #Heme #Synthesis ... #Porphyria #NEJM
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
Chronic GVHD #Pathophys ... #Honc #Pharm #GVHD ... Therapeutic #Pathways #NEJM
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Oxidative Damage #Pathophys ... Peds #Genetics #Honc ... #Favism #g6pd #NEJM
Paths to Defective Homologous Recombination DNA Repair in Breast Cancer. Each individual mutation or epigenetic aberration
breast cancer #Pathophys ... #Honc #BreastCancer ... #DNARepair #NEJM
#Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
#Pathophys #Peds ... #Genetics #Honc ... #Favism #g6pd #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Stage III or IV Melanoma ... Population #EBM #Honc ... Nivolumab #Ipilimumab #Melanoma ... #NEJM
Melanoma of the Foot - The physical examination revealed a well-defined, fleshy, reddish plaque measuring 2
Melanoma of the ... A melanoma with ... Derm #Podiatry #Honc ... AmelanoticMelanoma #Amelanotic #Melanoma ... #Foot #NEJM
Upper endoscopy revealed a pigmented mass in the duodenal bulb (Panel A) and two additional masses
Clinical #GI #Derm #Honc ... #Melanoma #Duodenum ... EGD #Metastatic #NEJM